Jpmorgan Chase & CO Procept Bio Robotics Corp Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 812,366 shares of PRCT stock, worth $75.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
812,366
Previous 896,747
9.41%
Holding current value
$75.3 Million
Previous $54.8 Million
18.79%
% of portfolio
0.01%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PRCT
# of Institutions
266Shares Held
38MCall Options Held
262KPut Options Held
257K-
Vanguard Group Inc Valley Forge, PA4.84MShares$449 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$323 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY1.53MShares$142 Million0.04% of portfolio
-
Loomis Sayles & CO L P1.24MShares$115 Million0.13% of portfolio
-
State Street Corp Boston, MA1.18MShares$109 Million0.0% of portfolio
About PROCEPT BioRobotics Corp
- Ticker PRCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 44,592,300
- Market Cap $4.13B
- Description
- PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...